Presentation is loading. Please wait.

Presentation is loading. Please wait.

Endocrine System KNH 411.

Similar presentations


Presentation on theme: "Endocrine System KNH 411."— Presentation transcript:

1 Endocrine System KNH 411

2 Diabetes Mellitus 7% of population; 1/3 undiagnosed
$132 billion in health care Sixth leading cause of death Complications of diabetes (DM) Majority type 2

3 Type 1 DM Pathophys/clinical manifestations
Inability of cells to use glucose for energy Hyperglycemia and cells starve Polyuria Polydipsia Polyphagia Unexplained weight loss

4 Type 1 DM Pathophys/clinical manifestations Lipolysis
Fatty acids transformed to ketones - pH falls Ketosuria Metabolic acidosis/ ketoacidosis High level of ketones is usually reason why person goes to hospital Extreme illness,

5 Type 1 DM Pathophys/clinical manifestations Hypovolemia
Potassium, sodium, magnesium, phosphorus lost Decreased Hg, Hct, protein, WBC, creatinine, serum osmolality Weight loss Hypovolemic shock Deep, labored breathing

6

7 © 2007 Thomson - Wadsworth

8 Type 1 DM Measures of Glycemic Control Glycated Hemoglobin** (A1C)**
Higher glucose- education and discussion Avg. concentration previous 2-4 mo. Regular basis Not recommended for dg of DM (A1C) Measured at least 2X per year Inappropriate for pt. with anemias/blood disorders

9 Type 1 DM Measures of Glycemic Control SMBG
Drop of blood via finger prick 3 or more times daily Assists in adjustment for eating and medication patterns Identifies food, exercise, other patterns that affect glycemic control

10 Type 1 DM Measures of Glycemic Control Fructosoamine
Glycemic control over 1-3 wk. period Not reliable with renal or liver disease Urine testing for glucose Renal threshold - glucose > 250 Urine testing for ketones Should be tested when glucose > 300

11 Type 1 DM Treatment risk factors Daily exogenous insulin
Nutrition therapy Exercise

12 Type 1 DM Treatment - Types of Insulin
Meant to mimic normal physiological action of insulin Classified based on onset of action, peak time, duration of action Dosage typically based on body weight, adjusted based on blood glucose levels

13 Type 1 DM Treatment - Insulin Regimens Fixed/conventional/standard
Flexible/intensive Continuous infusion (CSII)

14 Type 1 DM Treatment - Insulin Regimens Fixed/conventional/standard
Constant dose of basal insulin With short or rapid (bolus) insulin “Mixed dose” or split mixed dose Must synchronize insulin with food intake

15 Type 1 DM Treatment - Insulin Regimens Flexible
Multiple daily injections Bolus insulin before meals Basal insulin once or twice daily More flexibility

16 Type 1 DM Treatment - Insulin Regimens Continuous infusion
Basal rapid or short Boluses are given before meals

17

18 Type 1 DM Nutrition Therapy Should be individualized! Based on:
Self care treatment plan Learning ability Current lifestyle

19 Type 1 DM Nutrition Therapy CHO Alcohol kcal considered additional
Meal planning Individualized

20 Type 1 DM Nutrition therapy Carbohydrate counting
Consistent amount of CHO at meals and snacks Count starches, fruits, milk/yogurt, sweets Count amount of food containing 15 g CHO or Total grams of CHO 3 skill levels

21 Type 1 DM Nutrition therapy Exchange System
Exchange Lists for Meal Planning Substitution of different foods with each of 3 groups Each food on particular list can be substituted with food on same list

22 Type 1 DM Short-term illness Supplemental insulin Replacement fluids
Electrolytes Glucose SMBG Urine testing Prevent progression Less than 24 hrs.

23 Type 2 DM 90-95% of diagnosed cases Adults, elderly, persons of color
Increased risk traits

24 Type 2 DM Pathophysiology Insulin resistance
Pancreas increases production Pancreas stops producing insulin Insulin deficiency Glucose intolerance DM develops in obese Hyperglycemia develops

25 Type 2 DM Metabolic syndrome Central obesity Insulin resistance
Dyslipidemia Hypertension

26 Type 2 DM Clinical Manifestations Insidious
Criteria for testing based on risk factors including PCOS Disease may progress

27 Type 2 DM Treatment Glycemic control depends on: Nutrition therapy
Hepatic glucose production Glucose uptake by periphery Absorption of glucose from food Nutrition therapy Physical activity Medications

28 Type 2 DM Nutrition Therapy Plan based on metabolic priorities
Lifestyle and behavior modification Weight management Monitor total CHO < 20% pro. Dietary fat goals for CVD 14 grams fiber/1000 kcal


Download ppt "Endocrine System KNH 411."

Similar presentations


Ads by Google